Liquid Biopsy of Breast Cancer Update with Founder of Savran Tech.

Angel Invest Boston

Sponsored by:

• Purdue University entrepreneurship
• Peter Fasse, patent attorney at Fish & Richardson

In December of 2017 I interviewed Çağrı Savran, Ph.D. about plans for his startup in which I had just invested. Almost four years later I interviewed him again to review the progress of the company which is changing the way breast cancer is followed up after treatment.

Highlights:

• Update on the Original Interview with Çağrı Savran, Ph.D.
• In December of 2017 Savran Was Operating with Essential Components Handmade in the Lab – In October 2021 the Main Components Are Produced by a Vendor
• Early Technology Was Used in a Major Clinical Trial at Indiana University School of Medicine and Significantly Improved Prediction of Recurrence of a Breast Cancer
• The Existing Technology for Capturing Circulating Tumor Cells Is Not Scalable – Savran’s Tech Is Amenable to Scale
• Strategic Players in Prenatal Diagnostics Are Interested in Sequencing the Cells Captured – Savran Is Uniquely Positioned to Provide That Ability
• The Basic Technology Is Like a Kitchen, the Different Assays Are Like What’s Being Prepared in the Kitchen
• Savran Has Recruited a Capable and Involved Board
• Sal Daher Summarizes Savran’s Progress in the Last Four Years